EWTX vs PAR Comparison

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

PAR Technology Corp together with its subsidiaries provides management technology solutions including software, hardware, and related services, integral to the point-of-sale infrastructure and task management, information gathering, assimilation, and communication services. It has two segments. The restaurant/ Retail segment provides point-of-sale and management technology solutions such as hardware, software, and integrated technical solutions to the restaurant and retail industries. The government segment provides intelligence, surveillance, and reconnaissance solutions and mission systems support. The company derives the majority of its revenues from the Restaurant/ Retail segment.